BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update
15. November 2021 06:00 ET
|
BiomX
Announces Strategic Focus on Cystic Fibrosis and Atopic Dermatitis Programs Based on Potential Proof-of-Concept Clinical Data Readouts in 2022 Cash Runway Now Extended to End of 2023, Well Beyond Key...
BiomX to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 15, 2021
09. November 2021 08:00 ET
|
BiomX
NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage...
BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study
18. Oktober 2021 07:00 ET
|
BiomX
12-Week Study of BX001 Meets Safety and Tolerability Endpoints Statistically Significant Improvement from Baseline Observed in Appearance of Acne-prone Skin but No Meaningful Difference Demonstrated...
BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005
13. Oktober 2021 07:00 ET
|
BiomX
BRANFORD, Conn. and NESS ZIONA, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and...
BiomX to Present at Upcoming September Investor Conferences
02. September 2021 16:05 ET
|
BiomX
BRANFORD, Conn. and NESS ZIONA, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural...
BiomX Reports Second Quarter 2021 Financial Results and Provides Business Update
16. August 2021 06:30 ET
|
BiomX
Up to $45 Million Secured from Recent Capital Raises Extends Cash Runway to at Least Mid-2023 Expecting Four Clinical Data Readouts by Mid-2022 Company Will Host a Conference Call and Webcast Today...
BiomX to Host Second Quarter 2021 Financial Results Conference Call and Webcast on August 16, 2021
12. August 2021 08:00 ET
|
BiomX
NESS ZIONA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage...
BiomX Inc. Announces $15 Million Registered Direct Offering
26. Juli 2021 08:13 ET
|
BiomX
NESS ZIONA, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage...
BiomX To Host Key Opinion Leader Event on BX003 for the Treatment of Inflammatory Bowel Disease
18. Mai 2021 08:00 ET
|
BiomX
NESS ZIONA, Israel, May 18, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage...
BiomX Hosting Key Opinion Leader Symposium on Novel Phage Product for Acne Prone Skin
09. September 2019 08:00 ET
|
BiomX
NESS ZIONA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, today announced that it will host a Key Opinion Leader...